Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis

BACKGROUND: Progression-free survival (PFS) has been adopted as the primary endpoint in many randomized controlled trials, and can be determined much earlier than overall survival (OS). We investigated whether PFS is a good surrogate endpoint for OS in trials of first-line treatment for epithelial o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sjoquist, Katrin M., Lord, Sarah J., Friedlander, Michael L., John Simes, Robert, Marschner, Ian C., Lee, Chee Khoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080081/
https://www.ncbi.nlm.nih.gov/pubmed/30093922
http://dx.doi.org/10.1177/1758835918788500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080081/
https://www.ncbi.nlm.nih.gov/pubmed/30093922
http://dx.doi.org/10.1177/1758835918788500

Ejemplares similares